Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia
- 5 December 2019
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 188 (6), 881-887
- https://doi.org/10.1111/bjh.16261
Abstract
The day 14 bone marrow aspirate and biopsy (D14BM) is regularly used to predict achievement of complete remission (CR) with induction chemotherapy in acute myeloid leukemia (AML), however its utility has been questioned. Clearance of peripheral blood blasts (PBB) may serve as an early measure of chemosensitivity. PBB rate of clearance (PBB‐RC) was calculated for treatment‐naive AML patients (n = 164) undergoing induction with an anthracycline and cytarabine (7+3) and with detectable PBB at diagnosis. PBB‐RC was defined as the percentage of the absolute PBB count on the day of diagnosis that was cleared with each day of therapy, on average, until D14 or day of PBB clearance. Each 5% increase in PBB‐RC approximately doubled the likelihood of D14BM clearance (OR = 1·81; 95% CI: 1·24–2·64, P < 0·005). PBB‐RC was also associated with improved CR rates (OR per 5% = 1·97; 95% CI: 1·27–3·01, P < 0·005) and overall survival (OS) [hazard ratio (HR) per 5% = 0·67; 95% CI: 0·52–0·87]. African American patients had poorer OS adjusted for PBB‐RC (HR = 2·18; 95% CI: 1·13–4·23), while race was not associated with D14BM or CR rate. PBB‐RC during induction chemotherapy is predictive of D14BM clearance, CR, and OS, and can therefore serve as a prognostic marker for clinical outcomes in AML.This publication has 14 references indexed in Scilit:
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- A new model to predict remission status in AML patients based on day 14 bone marrow biopsyLeukemia Research, 2016
- Early Peripheral Blood Blast Clearance: A New Chemosensitivity Indicator for Acute Myeloid LeukemiaSAJ Cancer Science, 2014
- Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupHaematologica, 2013
- Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemiaCancer, 2012
- Is a nadir bone marrow required and, if so, what to do with residual disease?Best Practice & Research Clinical Haematology, 2011
- Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS studyLeukemia, 2008
- Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemiaAmerican Journal of Hematology, 2008
- Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survivalBlood, 2007
- Proposed Revised Criteria for the Classification of Acute Myeloid LeukemiaAnnals of Internal Medicine, 1985